Skip to main content
Alcohol Use DisorderAddictionMental healthDrugPhase 2, Phase 3

What this study is

This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

What's being tested

  • Cannabidiol

    Intervention · DRUG

    The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.

  • Placebo

    Intervention · DRUG

    Placebo arm.

Study details

Official title
Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies
Sponsor
University of Colorado, Denver
Conditions
Alcohol Use Disorder
Enrolling
180 people
Starts
2023-04-30
Est. completion
2027-04
Design
Quadruple-blind, randomized, parallel groups, Phase 2, Phase 3
Record
View on ClinicalTrials.gov ↗